

Vth International Conference on Cancer-Induced Bone Disease (CIBD)



Davos, Switzerland,
Sunday, March 20 – Thursday, March 24, 2005

EXECUTIVE COMMITTEE

Rob Coleman (Sheffield, UK)
Herbie Fleisch (Pully, Switzerland)
Jack Martin (Melbourne, Australia)
Greg Mundy (San Antonio, USA)
Etsuro Ogata (Tokyo, Japan)

SCIENTIFIC COMMITTEE

Bart Barlogie (Little Rock, USA)
Richard Bell (Geelong, Australia)
Jean-Jacques Body (Brussels, Belgium)
Oyvind Bruland (Oslo, Norway)
Philippe Clézardin (Lyon, France)
Denis Clohisy (Minneapolis, USA)
Peter Croucher (Sheffield, UK)
Ignac Fogelman (London, UK)
Matthew Gillespie (Melbourne, Australia)
Rob Grimer (Birmingham, UK)
Freddie Hamdy (Sheffield, UK)
Gabriel Hortobagyi (Houston, USA)
Toshio Matsumoto (Tokushima, Japan)
Suresh Mohla (Bethesda, USA)
Gabri van der Pluijm (Leiden, The Netherlands)
John Shaughnessy (Little Rock, USA)
Matt Smith (Boston, USA)
Kathy Weilbacher (St. Louis, USA)
Toshiyuki Yoneda (Osaka, Japan)

FORMAT

Plenary talks
Invited 30 minute lectures
Satellite meetings
Oral presentations

The Conference CME-0231 has been awarded 24 CME credit points by the Accreditation Council of Oncology in Europe (ACOE).

SUNDAY PM

2 pm **Registration and Poster Mounting**

4.55 pm Official conference opening and welcome
Rob Coleman and Herbie Fleisch

Chairmen: Jack Martin and Rob Coleman

5 pm Keynote lecture on bone biology:
The bone microenvironment and
metastasis
Greg Mundy (San Antonio, USA)

5.45 pm Keynote lecture on cancer treatment:
Targeted therapies for breast cancer
Gabriel Hortobagyi (Houston, USA)

6.30 – 7.30 pm **Reception**

MONDAY AM

Chairman: Greg Mundy (San Antonio, USA)

- 8.30 am Functions of the proteasome:
From protein breakdown and immune
surveillance to cancer therapy and
cachexia
Alfred Goldberg (Boston, USA)
- 9 am Total therapy (TT) for newly diagnosed
multiple myeloma (MM): The Arkansas
experience with 1000 patients treated on
TT1, 2, 3
Bart Barlogie (Little Rock, USA)
- 9.30 am Role of altered Wnt signaling in myeloma
and development of corresponding
therapeutic interventions
John Shaughnessey (Little Rock, USA)
- 10 am Wnt signaling in myeloma – paracrine and
autocrine mechanisms
**Steven Pals (Amsterdam,
The Netherlands)**

10.30 – 10.45 am Coffee break

Chairmen: G. van der Pluijm and J.-J. Body

- 10.45 am **Basic Mechanisms**
Selected 10 minute oral presentations from
posters
- 35:**
Secreted Wnt inhibitors are expressed by
breast cancer cell lines
Karl Häusler (Melbourne, Australia)

36:

RANK ligand directly induces osteoclasto-
genic, angiogenic, chemoattractive and
invasive factors on RANK-expressing
human cancer cells MDA-MB-231 and PC3
Bill Dougall (Seattle, USA)

37:

Expression of PTHrP, RANKL, OPG and
OCIL in multiple myeloma are influenced
by the tumor cells' proximity to bone
**Vicky Kartsogiannis (Melbourne,
Australia)**

38:

Myeloma cells inhibit osteoblastogenesis
and block Runx2/Cbfa1 activity in human
bone marrow osteoblast progenitors
Nicola Giuliani (Parma, Italy)

39:

Integrin $\alpha v \beta 3$ is critical for human breast
cancer bone metastasis
Yingshe Zhao (Lyon, France)

Chairman: Peter Croucher (Sheffield, UK)

- 11.35 am MIP 1 produced by myeloma cells en-
hances bone destruction, myeloma cell
survival, and suppresses dendritic cell
formation
Toshio Matsumoto (Tokushima, Japan)
- 12.05 pm Facilitation of myeloma colonization in
bone by $\alpha 4 \beta 1$ integrin-VCAM-1 interactions
Toshiyuki Yoneda (Osaka, Japan)

MONDAY PM

12.35 – 3.30 pm	Free time
3.30 – 4.30 pm	Coffee/tea and poster viewing
4.30 – 6 pm	AMGEN satellite symposium The Potential Role of RANK Ligand Inhibition in Cancer-Induced Bone Disease RANK ligand inhibition: From discovery to pre-clinical proof of concept – Preclinical overview – AMG 162 vs OPG Bill Dougall (Seattle, USA) Potential anti-tumor effects of RANK ligand inhibition – Overview of literature – Multiple myeloma data Peter Croucher (Sheffield, UK) Clinical data with AMG 162: Results to date and clinical opportunities – Phase 1 data oncology – Design of phase 1 bone mets trials – Design of phase 3 hormone ablation bone loss trials (HALT) Jean-Jacques Body (Brussels, Belgium) Chairman: Suresh Mohla (Bethesda, USA)
6 pm	Non-osseous effects of osteoprotegerin Peter Croucher (Sheffield, UK)
6.30 pm	Genetic analysis of systemic breast cancer progression Christoph Klein (Munich, Germany)
7 pm	Identification of molecular apocrine breast tumours by microarray analysis Richard Iggo (Lausanne, Switzerland)

TUESDAY AM

Chairman: Toshiyuki Yoneda (Osaka, Japan)	
8.30 am	Cellular interaction and tropism of prostate cancer to bone Leland WK Chung (Atlanta, USA)
9 am	A novel integrin antagonist: Evaluation in bone growth tumour models Philippe Clezardin (Lyon, France)
9.30 am	Tumour and bone effects of PTHrP: implications for breast cancer behaviour Matthew Gillespie (Melbourne, Australia)
10 – 10.15 am	Coffee break
Chairmen: Philippe Clézardin & Richard Bell	
10.15 am	Therapeutic approaches Selected 10 minute oral presentations from posters 40: HTLV1-tax transgenic mice develop spontaneous osteolytic bone disease prevented by osteoclast inhibition Kathy Weilbaecher (St. Louis, USA) 41: Role of Dickkopf 1 (DKK1) in myeloma bone disease and modulation by the proteasome inhibitor Velcade Babatunde Oyajobi (San Antonio, USA) 42: LPA: A new local factor acting on breast cancer bone metastasis Ahmed Bucharaba (Lyon, France)

43:

The HSP90 pharmacological inhibitor, 17-AAG, enhances breast-bone metastasis in nude mouse model and stimulates *In Vitro* and *In Vivo* osteoclast formation
John Price (Melbourne, Australia)

44:

Osteoclasts as a bone tumor-targeted gene delivery system
Denis R. Clohisy (Minneapolis, USA)

45:

Understanding drug sequence-dependent synergistic induction of apoptosis by Zoledronic acid (ZOL) and Doxorubicin (DOX) in breast cancer
Helen Neville-Webbe (Sheffield, U.K.)

46:

Radiation treatment decreases bone cancer pain through direct effect on tumor cells
Denis R. Clohisy (Minneapolis, USA)

Chairman: Toshio Matsumoto (Tokushima, Japan)

11.30 am Epithelium-mesenchyme transition in bone metastasis: New therapeutic opportunities
Gabri van der Pluijm (Leiden, The Netherlands)

Noon Src kinase inhibitors in bone disease
Brendan Boyce (Boston, USA)

TUESDAY PM

12.30 – 3.30 pm **Free time**

3.30 – 4.30 pm Coffee/tea and poster viewing

4.30 – 6 pm **Novartis satellite symposium**

**Evidence & Experience:
Zoledronic Acid in CIBD**

4.30 – 4.35 pm Introduction
Gabriel Hortobagyi (Houston, USA)

4.35 – 5.05 pm Zoledronic acid in the therapy of cancer induced bone disease:
Corroborating the evidence
Matthew Smith (Boston, USA)

5.05 – 5.25 pm Anti-tumour activity of Zoledronic acid
Philippe Clézardin (Lyon, France)

5.25 – 5.45 pm Moving into the future: Treatment of bone metastases and beyond
Gabriel Hortobagyi (Houston, USA)

5.45 – 5.55 pm Questions and answers

5.55 – 6 pm Summary, conclusions and close
Gabriel Hortobagyi (Houston, USA)

Chairman: Freddie Hamdy (Sheffield, U.K.)

6 pm What's new in breast cancer management?
Richard Bell (Geelong, Australia)

6.30 pm Advances in treatment approaches to prostate cancer
George Thalmann (Bern, Switzerland)

7 pm Mechanisms that drive bone cancer pain
Patrick Mantyh (Minneapolis, USA)

WEDNESDAY AM

Chairman: Herbie Fleisch (Pully, Switzerland)

8.30 am Do bisphosphonates act on tumour cells as well as on bone cells?

Mike Rogers (Aberdeen, UK)

9 am Developing more rational use of bisphosphonates in malignancy
Rob Coleman (Sheffield, UK)

9.30 am PET in malignancy of the skeleton
Ignac Fogelman (London, UK)

10 – 10.15 am Coffee break

Chairmen: Richard Bell & Matthew Smith

10.15 am **Clinical studies**
Selected 12 minute oral presentations from posters

47:

Heterogeneity of bone formation and resorption in prostate cancer bone metastasis

Martine Roudier (Bothell, USA)

48:

Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone

Fred Saad (Montreal, Canada)

49:

Zoledronic acid provides long-term reduction of bone pain in patients with bone metastases secondary to breast cancer

Allan Lipton (Hershey, USA)

50:

Using bone turnover markers to direct bisphosphonate therapy: is this a feasible approach?

Janet Brown (Sheffield, U.K.)

51:

Clinical experiences using radium-223, a novel alpha-emitting bone seeking radio-pharmaceutical, in breast and prostate cancer patients with skeletal metastases

Oyvind Bruland (Oslo, Norway)

52:

Adjuvant chemotherapy for pre-menopausal breast cancer induces significant loss of bone mineral density independent of ovarian suppression

David Cameron (Edinburgh, U.K.)

Chairman: Rob Grimer (Birmingham, UK)

11.30 am Surgical strategy for spinal metastatic disease

Alistair Stirling (Birmingham, UK)

Noon Surgical treatment for pathological fracture

Henrik Bauer (Stockholm, Sweden)

WEDNESDAY PM

12.30 – 3.30 pm	Free time
3.30 – 4.30 pm	Coffee/tea and poster viewing
4.30 – 6 pm	Roche satellite symposium Bondronat®: Maximising renal safety in metastatic bone disease

Chairman: Jean-Jacques Body (Brussels, Belgium)

4.30 – 4.35 pm	Welcome Jean-Jacques Body (Brussels, Belgium)
4.35 – 5 pm	Bondronat®: relieving metastatic bone pain without compromising renal safety Richard Bell (Geelong, Australia)
5 – 5.25 pm	Safety issues influence choice Graham Jackson (Newcastle upon Tyne, U.K.)
5.25 – 5.50 pm	Renal safety: where do we go from here? Roger von Moos (Chur, Switzerland)
5.50 – 6 pm	Closing remarks Jean-Jacques Body (Brussels, Belgium)

Chairman: Oyvind Bruland (Oslo, Norway)

6 pm	Pain and structural effects of external beam radiotherapy Ed Chow (Toronto, Canada)
6.30 pm	Radio-isotope treatments for bone metastases Valerie Lewington (London, UK)
7 pm	Minimally invasive surgery for spinal metastasis Richard Schlenk (Cleveland, USA)

THURSDAY AM

Chairman: Jean-Jacques Body (Brussels, Belgium)

8.30 am	Treatment-related osteoporosis in men with prostate cancer Matthew Smith (Boston, USA)
9 am	Aromatase inhibitors and bone Richard Eastell (Sheffield, UK)
9.30 am	Role of bone turnover markers in cancer induced bone disease Pierre Delmas (Lyon, France)
10 am	Lessons from post menopausal osteoporosis for cancer clinicians Socrates Papapoulos (Leiden, The Netherlands)
10.30 – 10.45 am	Coffee break
10.45 – 11.30 am	CAB society inaugural AGM
11.30 – 12.30 pm	20 minute oral presentations from tree of the top ranked posters 32: Gli2 regulates PTHrP expression and tumor induced osteolysis by metastatic breast cancer cells Julie A. Sterling (San Antonio, USA) 33: Use of bisphosphonate analogs of rise-dronate to elucidate antiangiogenic mechanisms of bisphosphonates <i>In Vivo</i> Pierrick Fournier (Lyon, France) 34: Onset of time to first skeletal-related event in patients with advanced cancer metastatic to bone and the clinical benefit of bisphosphonates Matti Aapro (Genolier, Switzerland)
12.30 pm	Close of meeting

CONGRESS SECRETARIAT:

Heidi Triet
Office Prof. H. Fleisch
Effingerstrasse 40
CH-3008 Bern
Switzerland
Tel. +41 31 389 92 76
Fax +41 31 389 92 84
e-mail: secretariat@hfleisch.ch

OR CONTACT AT THE MEETING:

Tel. +41 81 414 64 07
Fax +41 81 414 64 26
e-mail: secretariat@hfleisch.ch

OR SEE ON

<http://ibmsonline.org/cancerbone.htm>
for the Vth CIBD Davos 2005